
Sign up to save your podcasts
Or


On This episode of Stock Movers:
- Novo Nordisk won approval to sell a pill version of its blockbuster obesity shot Wegovy in the US, a crucial step in its effort to defend its market share from rival Eli Lilly.
- Ryanair was fined more than €255 million ($300 million) by Italy’s antitrust watchdog for allegedly using an “abusive strategy” to thwart third-party travel agencies.
- Cevian Capital raises its total holding in Akzo Nobel NV to 10.15% from ~5%, according to a filing with the Dutch financial authority AFM.
See omnystudio.com/listener for privacy information.
By iHeartPodcasts4.6
1919 ratings
On This episode of Stock Movers:
- Novo Nordisk won approval to sell a pill version of its blockbuster obesity shot Wegovy in the US, a crucial step in its effort to defend its market share from rival Eli Lilly.
- Ryanair was fined more than €255 million ($300 million) by Italy’s antitrust watchdog for allegedly using an “abusive strategy” to thwart third-party travel agencies.
- Cevian Capital raises its total holding in Akzo Nobel NV to 10.15% from ~5%, according to a filing with the Dutch financial authority AFM.
See omnystudio.com/listener for privacy information.

405 Listeners

1,168 Listeners

2,171 Listeners

1,943 Listeners

414 Listeners

1,048 Listeners

1,302 Listeners

62 Listeners

65 Listeners

155 Listeners

81 Listeners

80 Listeners

72 Listeners

8 Listeners

2 Listeners